FDA Holds on Moderna Inc, Pfizer Inc, and Novavax Inc Combination Covid-Flu Shot Shakes the Health Care Industry
Wednesday, 16 October 2024, 14:21
FDA Holds on Covid-Flu Shot from Moderna Inc, Pfizer Inc, and Novavax Inc
The recent decision by the FDA to impose a clinical hold on the combination Covid-flu shot developed by Moderna Inc, Pfizer Inc, and Novavax Inc has taken investors by surprise.
Clinical Hold Details
- The hold is linked to a single report of nerve damage in a patient who participated in a phase two trial.
- This incident raises significant concerns regarding the safety and efficacy of the new vaccine.
- Shares of the affected companies have sharply declined following the announcement.
Market Reactions
Investors in the health care industry, particularly those focusing on the biotech and pharmaceuticals sectors, should be vigilant as further reporting unfolds.
For more insights on the situation and its implications for the pharmaceutical business landscape, keep an eye on upcoming updates.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.